Biomea Fusion, Inc. Comprehensive Income
Biomea Fusion, Inc. (BMEA) reported Comprehensive Income of -$8.33 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-05
- Biomea Fusion, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$8.33M.
- Biomea Fusion, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$12.41M.
- Biomea Fusion, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was $4.61M.
- Biomea Fusion, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$16.41M.
- Biomea Fusion, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$61.80M.
- Biomea Fusion, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$138.43M.
- Biomea Fusion, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$117.25M.
- Biomea Fusion, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$81.82M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$8.33M 10-Q · filed 2026-08-05 | -$20.74M 10-Q · filed 2026-08-05 | -$16.13M derived: sum of 3 quarters · filed 2026-08-05 | -$32.54M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$12.41M 10-Q · filed 2026-05-11 | -$7.80M derived: sum of 2 quarters · filed 2026-05-11 | -$24.21M derived: sum of 3 quarters · filed 2026-05-11 | -$44.95M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $4.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$11.79M derived: sum of 2 quarters · filed 2026-03-24 | -$32.53M derived: sum of 3 quarters · filed 2026-08-05 | -$61.80M 10-K · filed 2026-03-24 |
| 2025-09-30 | -$16.41M 10-Q · filed 2025-11-04 | -$37.15M derived: sum of 2 quarters · filed 2026-08-05 | -$66.41M 10-Q · filed 2025-11-04 | -$95.71M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$20.74M 10-Q · filed 2026-08-05 | -$50.00M 10-Q · filed 2026-08-05 | -$79.30M derived: sum of 3 quarters · filed 2026-08-05 | -$112.09M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$29.26M 10-Q · filed 2026-05-11 | -$58.56M derived: sum of 2 quarters · filed 2026-05-11 | -$91.35M derived: sum of 3 quarters · filed 2026-05-11 | -$128.63M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$29.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$62.09M derived: sum of 2 quarters · filed 2026-03-24 | -$99.36M derived: sum of 3 quarters · filed 2026-03-24 | -$138.43M 10-K · filed 2026-03-24 |
| 2024-09-30 | -$32.79M 10-Q · filed 2025-11-04 | -$70.06M derived: sum of 2 quarters · filed 2025-11-04 | -$109.12M 10-Q · filed 2025-11-04 | -$144.01M derived: sum of 4 quarters · filed 2026-03-24 |
| 2024-06-30 | -$37.28M 10-Q · filed 2025-08-05 | -$76.34M 10-Q · filed 2025-08-05 | -$111.22M derived: sum of 3 quarters · filed 2026-03-24 | -$139.65M derived: sum of 4 quarters · filed 2026-03-24 |
| 2024-03-31 | -$39.06M 10-Q · filed 2025-05-05 | -$73.94M derived: sum of 2 quarters · filed 2026-03-24 | -$102.37M derived: sum of 3 quarters · filed 2026-03-24 | -$127.26M derived: sum of 4 quarters · filed 2026-03-24 |
| 2023-12-31 | -$34.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$63.31M derived: sum of 2 quarters · filed 2026-03-24 | -$88.20M derived: sum of 3 quarters · filed 2026-03-24 | -$117.25M 10-K · filed 2026-03-24 |
| 2023-09-30 | -$28.43M 10-Q · filed 2024-10-29 | -$53.32M derived: sum of 2 quarters · filed 2024-10-29 | -$82.37M 10-Q · filed 2024-10-29 | -$107.67M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-06-30 | -$24.89M 10-Q · filed 2024-07-31 | -$53.94M 10-Q · filed 2024-07-31 | -$79.24M derived: sum of 3 quarters · filed 2025-03-31 | -$102.13M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-03-31 | -$29.05M 10-Q · filed 2024-05-02 | -$54.35M derived: sum of 2 quarters · filed 2025-03-31 | -$77.24M derived: sum of 3 quarters · filed 2025-03-31 | -$94.49M derived: sum of 4 quarters · filed 2025-03-31 |
| 2022-12-31 | -$25.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$48.19M derived: sum of 2 quarters · filed 2025-03-31 | -$65.44M derived: sum of 3 quarters · filed 2025-03-31 | -$81.82M 10-K · filed 2025-03-31 |
| 2022-09-30 | -$22.89M 10-Q · filed 2023-10-30 | -$40.14M derived: sum of 2 quarters · filed 2023-10-30 | -$56.52M 10-Q · filed 2023-10-30 | -$71.24M derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-06-30 | -$17.25M 10-Q · filed 2023-07-31 | -$33.63M 10-Q · filed 2023-07-31 | -$48.35M derived: sum of 3 quarters · filed 2024-03-28 | -$60.96M derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-03-31 | -$16.38M 10-Q · filed 2023-05-02 | -$31.10M derived: sum of 2 quarters · filed 2024-03-28 | -$43.71M derived: sum of 3 quarters · filed 2024-03-28 | -$52.09M derived: sum of 4 quarters · filed 2024-03-28 |
| 2021-12-31 | -$14.72M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$27.33M derived: sum of 2 quarters · filed 2024-03-28 | -$35.71M derived: sum of 3 quarters · filed 2024-03-28 | -$41.58M 10-K · filed 2024-03-28 |
| 2021-09-30 | -$12.61M 10-Q · filed 2022-11-07 | -$20.99M derived: sum of 2 quarters · filed 2022-11-07 | -$26.86M 10-Q · filed 2022-11-07 | -$30.35M derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-06-30 | -$8.38M 10-Q · filed 2022-08-01 | -$14.25M 10-Q · filed 2022-08-01 | -$17.75M derived: sum of 3 quarters · filed 2023-03-28 | -$18.88M derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-03-31 | -$5.87M 10-Q · filed 2022-05-16 | -$9.37M derived: sum of 2 quarters · filed 2023-03-28 | -$10.50M derived: sum of 3 quarters · filed 2023-03-28 | -$10.79M derived: sum of 4 quarters · filed 2023-03-28 |
| 2020-12-31 | -$3.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | -$4.63M derived: sum of 2 quarters · filed 2023-03-28 | -$4.93M derived: sum of 3 quarters · filed 2023-03-28 | -$5.32M 10-K · filed 2023-03-28 |
| 2020-09-30 | -$1.14M 10-Q · filed 2021-11-03 | -$1.43M derived: sum of 2 quarters · filed 2021-11-03 | -$1.83M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | -$293.00K 10-Q · filed 2021-08-11 | -$691.00K 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | -$398.00K 10-Q · filed 2021-05-27 | |||
| 2019-12-31 | -$1.20M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |